Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Sleepman who wrote (11955)	12/1/1997 9:28:00 PM
From: William B. Kohn	Read Replies (1) \| Respond to of 32384

Considering where we are in the trials for these drugs, we may have concerns about almost anything. We are not even close to being out of the woods, heck we just stepped in the first row of trees in this forest. we could run into almost anything. But the real news is that if Ligands drugs have manageable side effects, there market just may have grown by a very significant amount. billk

To: Sleepman who wrote (11955)	12/2/1997 12:11:00 AM
From: Henry Niman	Respond to of 32384

LGND's retinoids have been in cancer patients for 3 years and I haven't seen any liver toxicity reports. Of course cancer patients are more willing to tolerate side effects because of the seriousness of their illness, but they usually have their blood checked on a fairly regular basis. I suspect that part of Rezulin's liver toxcicity concerns are related to the high concentration used. The appropriate concentration for Targretin for type II diabetes is being determined (and LGD1268 hasn't even entered the clinic yet).